Calculators
OncoCalendar
Kefah Mokbel, Professor of Medicine at Cardiff University School of Medicine, shared on LinkedIn:
“ABC8 Guidelines 2026: A new chapter in the management of advanced breast cancer
The 8th International Consensus Guidelines for Advanced Breast Cancer (ABC8) have been published in The Breast, providing a comprehensive, evidence-based update on the management of advanced and metastatic breast cancer. They reflect major advances in treatment while reinforcing the importance of personalised, patient-centred care.
Key highlights:
- HR+/HER2− disease: CDK4/6 inhibitors combined with endocrine therapy remain the preferred first-line approach for most patients. New evidence supports biomarker-guided treatment selection, including oral SERDs, PI3K/AKT pathway inhibitors and antibody–drug conjugates (ADCs).
- HER2+ disease: DESTINY-Breast09 introduces T-DXd plus pertuzumab as an important first-line option, while PATINA and HER2CLIMB-05 reshape maintenance strategies according to hormone receptor status.
- Triple-negative breast cancer: ASCENT-03, ASCENT-04 and TROPION-Breast02 highlight the expanding role of ADCs in first-line treatment, with treatment selection increasingly influenced by PD-L1 status, toxicity and individual patient characteristics.
- Precision oncology: Greater emphasis on actionable genomic alterations, including ESR1, PIK3CA/AKT/PTEN and HER2 mutations, with ctDNA testing increasingly integrated into therapeutic decision-making.
- Brain metastases: Consideration of CNS screening in selected high-risk patients, particularly when detection could influence systemic treatment decisions.
- Supportive care: Recognition of structured exercise, symptom management, quality of life and shared decision-making as essential components.
My key takeaway:
The challenge in advanced breast cancer is no longer simply identifying effective treatments. It is determining the right treatment, for the right patient, at the right time, in the right sequence, while balancing efficacy, toxicity, quality of life and access.
Importantly, ABC8 also reminds us that scientific progress does not automatically translate into equitable access. Addressing disparities in cancer care must remain a global priority.
Despite its comprehensive scope, ABC8 leaves important questions unanswered, particularly around optimal treatment sequencing, resistance to antibody–drug conjugates, and management of patients underrepresented in clinical trials.
Greater emphasis on real-world evidence, cumulative toxicity, quality of life, and practical strategies for equitable access would help bridge the gap between rapidly advancing science and truly personalised patient care.
Interestingly, ABC8 does not recommend using ctDNA to establish disease progression or routinely changing treatment solely because molecular progression is detected before radiological or clinical progression.”
Title: 8th International consensus guidelines for the management of advanced breast cancer (ABC8 guidelines)
Authors: Fatima Cardoso, Joana Mourato Ribeiro, Eva Schumacher-Wulf, Sandra M. Swain, Shani Paluch-Shimon, Frederique Penault-Llorca, Nancy U. Lin, Prudence A. Francis, Marion Kuper-Hommel, Anne May, Florentine Hilbers, Angel Guerrero, Matti S. Aapro, Rania Azmi, Jyoti Bajpai, Carlos Barrios, Laura Biganzoli, Fran Boyle, Valeria Caceres, Lisa A. Carey, Mariana Chavez-MacGregor, Javier Cortés, Rebecca Dent, Amanda Drury, Nagi S. El Saghir, Hesham Elghazaly, Alexandru Eniu, Lesley Fallowfield, Sandra Ximena Franco Millan, Karen Gelmon, Jenny Gilchrist, Joseph Gligorov, William J. Gradishar, Nadia Harbeck, Xichun Hu, Orit Kaidar-Person, Ranjit Kaur, Belinda Kiely, Sung-Bae Kim, Sarah Kutika Nyagabona, Maryam Lustberg, Volkmar Mueller, Miriam Mutebi, Silvia Neciosup, Shinji Ohno, Barbara Pistilli, Hope S. Rugo, Tanja Spanic, Janice Tsang, Peter Vuylsteke, Binghe Xu, Larry Norton, Eric P. Winer.
You can also read: ABC8 Guidelines Accepted for Publication: A More Molecular, Sequential, and Patient-Centered Framework for Advanced Breast Cancer.
